3 weeks Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of “Moderate Buy” by AnalystsMarketBeat
Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) has received an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock…
Nasdaq 100 · Pharmaceuticals · Science
X